Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Oncology·MeSH: Pancreatic Neoplasms
Prevalence
8.0 / 100K
Incidence
13.1 / 100K/yr
2 drugs in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 1(2)
Compare drugs
Frequently asked questions
How many drugs are in development for Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers?
BioSniper tracks 2 drugs in development for Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers across 1 company.
How many clinical trials target Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers?
There are 1 clinical trial targeting Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers tracked by BioSniper.
What is the prevalence of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers?
The estimated prevalence of Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers is approximately 8.0 per 100,000 population.
Deep-dive into Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis